Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
BioDlink International Co., Ltd. is clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. Its product portfolio includes: TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009 and is headquartered in Suzhou, China.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, 'expensive' on EV/
Target Price
The average target price of 1875.HK is 2.4 and suggests 42% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d
Buy
Sell